Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

IGC Pharma (IGC) Operating Income (2016 - 2025)

IGC Pharma (IGC) has disclosed Operating Income for 16 consecutive years, with -$2.9 million as the latest value for Q3 2025.

  • On a quarterly basis, Operating Income fell 64.72% to -$2.9 million in Q3 2025 year-over-year; TTM through Sep 2025 was -$2.1 million, a 77.02% increase, with the full-year FY2025 number at -$1.5 million, up 84.74% from a year prior.
  • Operating Income was -$2.9 million for Q3 2025 at IGC Pharma, down from -$1.9 million in the prior quarter.
  • In the past five years, Operating Income ranged from a high of $4.5 million in Q1 2025 to a low of -$6.5 million in Q1 2022.
  • A 5-year average of -$2.1 million and a median of -$2.4 million in 2021 define the central range for Operating Income.
  • Peak YoY movement for Operating Income: plummeted 259.22% in 2022, then skyrocketed 309.17% in 2025.
  • IGC Pharma's Operating Income stood at -$2.4 million in 2021, then increased by 6.0% to -$2.2 million in 2022, then tumbled by 33.72% to -$3.0 million in 2023, then soared by 37.36% to -$1.9 million in 2024, then tumbled by 54.37% to -$2.9 million in 2025.
  • Per Business Quant, the three most recent readings for IGC's Operating Income are -$2.9 million (Q3 2025), -$1.9 million (Q2 2025), and $4.5 million (Q1 2025).